Status:
COMPLETED
An EORTC Study Updating the QLQ-BR23 to BR45
Lead Sponsor:
University of Leeds
Collaborating Sponsors:
The Leeds Teaching Hospitals NHS Trust
European Organisation for Research and Treatment of Cancer - EORTC
Conditions:
Cancer
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Female breast cancer is still the most frequent type of cancer in Europe with 21 per 100,000 women .The EORTC QLQ-BR23 was one of the first modules developed to be used in conjunction with the core qu...
Eligibility Criteria
Inclusion
- Adult females aged 18 years or over
- Histologically confirmed diagnosis of breast cancer (any type) with no previous primary or recurrent tumour
- Receiving or have previously received curative or palliative treatment.
- Able to understand/speak English and complete the questionaires
- Have the capacity/mental fitness to give written informed consent and complete the questionnaires.
Exclusion
- Male gender or transgender
- Inability to understand/speak English and complete the questionnaire
- Patients with any psychiatric condition or cognitive impairment, as determined by the treating physician, that would hamper participation.
Key Trial Info
Start Date :
November 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04270123
Start Date
November 2 2020
End Date
January 31 2022
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leeds Teaching Hospitals NHS Trust
Leeds, West Yorkshire, United Kingdom, LS9 7TF